Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Icilma Fergus, MD
Healthcare Professional Director of Cardiovascular Disparities
Mount Sinai Medical Center
1 Gustave L Levy Place
New York, New York, United States
Icilma V. Fergus was recently appointed Director of Cardiovascular Disparities at Mount Sinai Medical Center. Her current academic appointment is Associate Professor of Clinical Medicine at Mount Sinai Medical Center in New York, New York. She is a Barnard and SUNY Downstate graduate. She completed her residency and Chief residency at Albert Einstein Medical Center. Dr. Fergus completed her cardiology fellowship at Weill Cornell Medical Center. She is board certified in internal medicine and cardiology.
Dr. Fergus’s current research interests involve cardiovascular disparities, hypertension and diastolic dysfunction as well as heart disease in women. She has been an investigator in several clinical trials including NHLBI sponsored trial evaluating acute ischemia in young women entitled “VIRGO” and DOH sponsored grant for Harlem Healthy Eating and Living.
Dr. Fergus is an active member of many professional memberships, including the American Society of Hypertension, American Society of Echocardiography, and the American College of Cardiology. Dr. Fergus served on the board of the Association of Black Cardiologists for six years including two years as secretary and has been the Chair of Community Programs for the past three years.
Representative Publications:
myBinderRelated Content
-
Mathew S. Maurer, MDDr. Mathew S. Maurer is medical director...
-
Julie L. Rosenthal, MDJulie L. Rosenthal is a Cardiologist-Int...
-
Association of Black CardiologistsFounded in 1974, the Association of Blac...
-
Acoramidis Reduces All-Cause, Cardiovascular Mortality at 30 Months in ATTR-CMThe 30-month results of the phase 3 ATTR...
-
Amyloidosis and the Heart: ATTR-Hereditary Amyloidosis Support Meetinghttps://www.dropbox.com/s/z9yjow0iojsqji...
-
Transthyretin Glu54Leu – An Unknown Mutation Within the Swedish Population Associated With Amyloid Cardiomyopa...For the first time, we report of a Swedi...
-
U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare a...Pfizer Inc. announced today that the U.S...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
